RxDoctor Payments Data

Ramy Fayad, MD

Nephrology · Toledo, OHNPI 1316069412

Payments from drug & device makers

$8,129in general payments, 2019–2025

Across 314 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$864
  • Mallinckrodt Hospital Products Inc.$781
  • AstraZeneca$771
  • Bayer$586
  • Vifor Pharma, Inc.$576
  • Otsuka America Pharmaceutical, Inc.$528
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,48492%
  • Education$6448%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,129 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$295,488
Medicare patients
478
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$556,290
XphozahTenapanor Hcl30$87,047
LokelmaSodium Zirconium Cyclosilicate83$72,595
FarxigaDapagliflozin Propanediol97$71,100
Sevelamer Carbonate180$47,972
AuryxiaFerric Citrate16$42,702
EliquisApixaban49$35,126
Bumetanide388$28,421
Lanthanum Carbonate21$23,261
Potassium Chloride108$22,044
JardianceEmpagliflozin32$18,823
Midodrine Hcl156$17,438
KerendiaFinerenone21$13,589
VeltassaPatiromer Calcium Sorbitex14$10,892
Clonidine50$10,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$74$556,29012 claims
AstraZenecaLokelma, Farxiga$771$143,695180 claims
Akebia Therapeutics IncAuryxia$424$42,70216 claims
PfizerEliquis$133$35,12649 claims
Boehringer IngelheimJardiance$184$18,82332 claims
BayerKerendia$586$13,58921 claims
NovartisEntresto$221$9,49114 claims
AbbVieLinzess$107$8,23214 claims
ANI Pharmaceuticals, Inc.Valsartan$114$93424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 nephrology providers in Ohio.

Other nephrology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →